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Dual Antiplatelet TherapyIn a post-hoc analysis, Yeh et al. (1) provide evidence
that dual-antiplatelet therapy with thienopyridine
and aspirin, for 30 (vs. 12) months after coronarystenting, had beneﬁcial effects regardless of whether
patients had acute myocardial infarction (MI) or less
acute presentations. In particular, stent thrombosis
was reduced—although bleeding was increased—
similarly in both groups. Clinicians should, however,
consider various elements of the study design when
interpreting results and using the ﬁndings in clinical
practice.
Importantly, the study classiﬁed patients with
unstable angina as having less acute (“no MI”) pre-
sentations. This subset accounted for nearly one-
fourth (22.6%) of the 8,072 patients without MI, or
roughly 1,800 patients—representing more than one-
half of the 3,576 patients with MI. Combining unsta-
ble angina patients within the non-MI group is of
more utility in allowing for conclusions to be drawn
on the MI group, given that the non-MI group repre-
sents a population of patients with a wide range of
risk of subsequent events—and it is unclear whether
the beneﬁcial effects of prolonged treatment was
driven by those at higher risk within this group.
Perhaps a sensitivity analysis could be done, ex-
cluding patients with unstable angina from the non-
MI group, to see if the overall results are affected.
From a more general perspective, the reader may
not immediately recognize that the current analyses
represent a post-hoc subgroup analysis of a previ-
ously completed randomized trial, with randomiza-
tion 12 months after initial enrollment. We would
defend the authors from reﬂexive criticisms that
such analyses are always problematic, but we
also note that whether the ﬁndings are valid, or
due to chance or bias, is always a consideration.
For example, lacking a formal power calculation
linked to antecedent MI status, the discordant
ﬁndings of similarly reduced stent thrombosis
without an interaction, compared to differential
reduction of major adverse cardiovascular and ce-
rebrovascular events with an interaction, have un-
certain implications.
Finally, as a speciﬁc methodological issue, the data
in Figure 1 in the paper by Yeh et al. (1) indicate that
(25,682 total minus 5,844 not eligible equals) 19,838
patients were eligible for randomization, but 8,190
were not randomized at 12 months for the reasons
stated. Given that this group represents (8,190
divided by 19,838 equals) 41.3% of eligible patients, it
would be useful to know whether pertinent baseline
characteristics (including the distribution of patients
in MI and non-MI groups) differ between analyzed
and excluded patients, for better understanding the
overall results.
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myocardial infarction. J Am Coll Cardiol 2015;65:2211–21.REPLY: Analysis of Dual Antiplatelet TherapyWe thank Dr. Ganeshan and colleagues for their in-
terest in our paper (1). In our subgroup analysis of the
DAPT Study (Dual Antiplatelet Therapy Study) (1),
continued thienopyridine therapy beyond 12 months
after coronary stent placement provided consistent
reductions in ischemic endpoints while increasing
bleeding in patients presenting initially with or
without myocardial infarction. Although not included
in our original publication, we have performed the
sensitivity analysis requested by Ganeshan and col-
leagues, grouping unstable angina patients with
myocardial infarction patients (acute coronary syn-
drome [ACS] group). In this analysis, consistent re-
ductions in ischemic endpoints were again observed
with continued thienopyridine in both ACS and non-
ACS patients (ACS group: stent thrombosis hazard
ratio [HR]: 0.35; p < 0.001, myocardial infarction HR:
0.47; p < 0.001; non-ACS group: stent thrombosis HR:
0.25, p < 0.001, myocardial infarction HR: 0.61;
p ¼ 0.002; interaction p ¼ NS for both comparisons).
GUSTO (Global Utilization of Streptokinase and Tis-
sue Plasminogen Activator for Occluded Coronary
Arteries) moderate or severe bleeding was increased
with continued thienopyridine in both groups as well
(ACS group HR: 2.01; p ¼ 0.002; non-ACS group HR:
1.49; p ¼ 0.024; interaction p ¼ 0.31).
As Dr. Ganeshan and colleagues rightly point out,
our study was a post-hoc subgroup analysis of a
completed randomized clinical trial (2,3) and was not
speciﬁcally powered to assess the interactions pre-
sented. Its conclusions should be interpreted with
this in mind.A large fraction of eligible patients were not ran-
domized in the DAPT study, primarily due to patient
and provider preference. Among myocardial infarc-
tion patients, those who were eligible, but not ran-
domized, were similar in age, but were more often
women (38.3% vs. 31.8%; p < 0.001), nonwhite (12.7%
vs. 8.4%), and had higher rates of diabetes, prior
stroke, congestive heart failure, and prior coronary
revascularization (p < 0.001 for each), as compared
with those randomized in the study. Similar results
were observed among patients without myocardial
infarction. These ﬁndings suggest that the random-
ized patients were somewhat lower risk for recurrent
ischemic events than those who were enrolled. It is
likely that had these eligible subjects also been ran-
domized, a treatment effect of the same magnitude or
larger would have been observed.Robert W. Yeh, MD, MSc
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Occlusion Devices Versus
Pharmacological Agents
for Stroke Prevention in
Atrial FibrillationIn evaluating the effectiveness of the Watchman
appendage occlusion device (AOD) in patients with
